All In Biotech

Drug Trial Radar · NCT06987851

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

An Extension, Multicenter, Open-Label, Non-Comparative Clinical Study of the Efficacy and Safety of Long-Term Use of BCD-132 (JSC BIOCAD) in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

Last checked: Nov 19, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

44

Actual

Start

Mar 22, 2022

Primary completion

May 16, 2024

Study completion May 16, 2024

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies

Conditions

  • Multiple Sclerosis

Interventions

  • DivozilimabBiological

    Intravenous infusion of BCD-132 every 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized relapse rateTime frame: 48 and 96 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Vyacheslav Andreyevich Dudin

    Kirov, Russia

  • Dmitry Vladimirovich Pokhabov

    Krasnoyarsk, Russia

  • Ivan Aleksandrovich Shchukin

    Moscow, Russia

  • Sergey Viktorovich Kotov

    Moscow, Russia

  • Elena Vladimirovna Parshina

    Nizhny Novgorod, Russia

  • Irina Aleksandrovna Sokolova

    Nizhny Novgorod, Russia

  • Gennady Nikolayevich Mishin

    Pyatigorsk, Russia

  • Yuri Vladimirovich Trinitatsky

    Rostov-on-Don, Russia

  • Zoya Aleksandrovna Goncharova

    Rostov-on-Don, Russia

  • Leonid Grigoryevich Zaslavsky

    Saint Petersburg, Russia

  • Natalya Agafonovna Totolyan

    Saint Petersburg, Russia

  • Irina Yevgenyevna Poverennova

    Samara, Russia

  • Valentina Mikhaylovna Alifirova

    Tomsk, Russia

  • Stella Anatolyevna Sivertseva

    Tyumen, Russia

  • Irina Vladimirovna Greshnova

    Ulyanovsk, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.